Diffuse Large B Cell Lymphoma Clinical Trials in Nashville, Tennessee

4 studies are recruiting for diffuse large b cell lymphoma in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

    The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Conf…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156), Nashville, Tennessee
    Locations
    135 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT05139017 on ClinicalTrials.gov

  2. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

    This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

    Stage
    Phase 1
    Ages
    13 to 90
    Site
    TriStar BMT, Nashville, Tennessee
    Locations
    11 in total
    Run by
    Vironexis Biotherapeutics Inc.

    See if you can join NCT06533579 on ClinicalTrials.gov

  3. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    SCRI Oncology Partners ( Site 7000), Nashville, Tennessee
    Locations
    285 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06717347 on ClinicalTrials.gov

  4. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

    Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Tennessee Oncology, Pllc Nashville, Nashville, Tennessee
    Locations
    114 in total
    Run by
    BeOne Medicines

    See if you can join NCT05006716 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.